Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Boston Scientific CEO Mike Mahoney says the company is still bullish on the prospects for its Vessix renal denervation platform for treating high blood pressure, despite the efficacy failure of Medtronic’s gold-standard Symplicity HTN-3 trial.
Medtech sales reps weigh in on the best jobs in medtech, ranking Medtronic at the top of the list.
Former President Bill Clinton tells an audience of healthcare stakeholders that if they hope to repeal the 2.3% medical device tax they’d better find a way to make up the funds.